Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOSS safety study of Biojector 2000 for Fuzeon administration in HIV infection
2016-000263-17Phase 4
- Sponsor
- Roche
- Start
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of enfuvirtide in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Roche. Primary endpoint: Composite injection site reaction endpoint.
02
Drugs
enfuvirtide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2016-000263-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000263-17.